About Company
We are Novartis, and we are reimagining medicine.
Headquartered in Basel, Switzerland, we are a leading global medicines company. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. We also aim to reward those who invest their money, time and ideas in our company.
Novartis medicines reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 76,000 people of more than 140 nationalities work at Novartis around the world.
Novartis has a significant presence in India, with a robust commitment to R&D towards expanding access to innovative medicines to patients.
In India, Novartis has had a significant footprint since 1947, committed to drug development, manufacturing, commercial and social business services. We have two legal entities namely, Novartis Healthcare Private Limited (NHPL) and Novartis India Limited (NIL) employing about 10,000 people.
We have consistently been recognized as a Top Employer, globally as well as in India.
Our rich portfolio of both innovative and established medicines address various therapeutic needs: cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India.
India is amongst a handful of countries in the world that have a broad Novartis footprint covering early research, drug development, technical operations, business services and commercial operations.
Impact on Economy
Over the last five years, Novartis has spent over USD 300 million in creating an R&D support center and services in India. One of the three major global development sites for Novartis, the Drug Development Centre in Hyderabad has integrated development capabilities and a strong operational footprint.
With an additional investment of USD 49 million, we are also in the process of expanding further by setting up a manufacturing plant at Kalwe. This plant would manufacture oral cancer medicines for the global market.
At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. Building trust with society with responsibility is a key pillar of the Novartis corporate strategy. It defines our approach to managing our key Environment, Social and Corporate Governance Goals (ESG) and Corporate responsibility topics and risks: being part of the solution on pricing and access, addressing global health challenges, being a responsible citizen, and holding ourselves to high ethical standards. We have long-standing commitment towards Zero Leprosy and Water Neutrality, amongst others.